Shanghai Yizhong Pharmaceutical Co Ltd (SHG:688091) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Yizhong Pharmaceutical Co Ltd (688091)
Shanghai Yizhong Pharmaceutical Co Ltd (SHG:688091) has a market capitalization of $1.25 Billion (CN¥8.56 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #8013 globally and #1848 in its home market, demonstrating a 5.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Yizhong Pharmaceutical Co Ltd's stock price CN¥41.41 by its total outstanding shares 206703640 (206.70 Million). Also see how large is Shanghai Yizhong Pharmaceutical Co Ltd's balance sheet for a full breakdown of the balance sheet.
Shanghai Yizhong Pharmaceutical Co Ltd Market Cap History: 2021 to 2026
Shanghai Yizhong Pharmaceutical Co Ltd's market capitalization history from 2021 to 2026. Data shows growth from $687.50 Million to $1.25 Billion (10.70% CAGR). Also see cash flow conversion of Shanghai Yizhong Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Shanghai Yizhong Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Yizhong Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Shanghai Yizhong Pharmaceutical Co Ltd (688091) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6.96x
Shanghai Yizhong Pharmaceutical Co Ltd's market cap is 6.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
173.11x
Shanghai Yizhong Pharmaceutical Co Ltd's market cap is 173.11 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $687.50 Million | $4.08 Million | -$4.00 Million | 168.61x | N/A |
| 2022 | $1.45 Billion | $235.96 Million | $142.85 Million | 6.16x | 10.18x |
| 2023 | $1.47 Billion | $360.25 Million | $161.55 Million | 4.09x | 9.12x |
| 2024 | $1.21 Billion | $173.53 Million | $6.98 Million | 6.96x | 173.11x |
Competitor Companies of 688091 by Market Capitalization
Companies near Shanghai Yizhong Pharmaceutical Co Ltd in the global market cap rankings as of September 24, 2026. Review Shanghai Yizhong Pharmaceutical Co Ltd tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shanghai Yizhong Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Shanghai Yizhong Pharmaceutical Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Shanghai Yizhong Pharmaceutical Co Ltd's market cap moved from $687.50 Million to $ 1.25 Billion, with a yearly change of 10.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.25 Billion | -11.89% |
| 2025 | CN¥1.42 Billion | +17.74% |
| 2024 | CN¥1.21 Billion | -18.04% |
| 2023 | CN¥1.47 Billion | +1.31% |
| 2022 | CN¥1.45 Billion | +111.52% |
| 2021 | CN¥687.50 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Shanghai Yizhong Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.25 Billion USD |
| MoneyControl | $1.25 Billion USD |
| MarketWatch | $1.25 Billion USD |
| marketcap.company | $1.25 Billion USD |
| Reuters | $1.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more